Research ExplorerPublicationsRenale Denervation bei nicht-kontrollierter arterieller Hype...

Renale Denervation bei nicht-kontrollierter arterieller Hypertonie

Standard

Renale Denervation bei nicht-kontrollierter arterieller Hypertonie. / Vonend, Oliver; Böhm, Michael; Eckert, Siegfried; Hausberg, Martin; Rittger, Harald; Rump, Lars-Christian; Schmieder, Roland; Schulte, Karl-Ludwig; Schunkert, Heribert; Uder, Michael; Veelken, Roland; Vorwerk, Dierk; Weil, Joachim; Wenzel, Ulrich; Mahfoud, Felix.

In: DEUT MED WOCHENSCHR, Vol. 140, No. 5, 03.2015, p. 363.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Vonend, O, Böhm, M, Eckert, S, Hausberg, M, Rittger, H, Rump, L-C, Schmieder, R, Schulte, K-L, Schunkert, H, Uder, M, Veelken, R, Vorwerk, D, Weil, J, Wenzel, U & Mahfoud, F 2015, 'Renale Denervation bei nicht-kontrollierter arterieller Hypertonie', DEUT MED WOCHENSCHR, vol. 140, no. 5, pp. 363. https://doi.org/10.1055/s-0041-100835

APA

Vonend, O., Böhm, M., Eckert, S., Hausberg, M., Rittger, H., Rump, L-C., Schmieder, R., Schulte, K-L., Schunkert, H., Uder, M., Veelken, R., Vorwerk, D., Weil, J., Wenzel, U., & Mahfoud, F. (2015). Renale Denervation bei nicht-kontrollierter arterieller Hypertonie. DEUT MED WOCHENSCHR, 140(5), 363. https://doi.org/10.1055/s-0041-100835

Vancouver

Vonend O, Böhm M, Eckert S, Hausberg M, Rittger H, Rump L-C et al. Renale Denervation bei nicht-kontrollierter arterieller Hypertonie. DEUT MED WOCHENSCHR. 2015 Mar;140(5):363. https://doi.org/10.1055/s-0041-100835

Bibtex

@article{b38efafa358e48628a488b2476c64dd2,
title = "Renale Denervation bei nicht-kontrollierter arterieller Hypertonie",
abstract = "Arterial hypertension is a major risk factor for cardiovascular mortality and remains insufficiently controlled in Germany. The sham controlled Symplicity HTN-3 trial did meet its primary safety endpoint but failed to meet its primary efficacy endpoint. Renal denervation can not replace established, well-proven therapies. It can only be used in selected truly resistant hypertensive patients as an additive approach and should be performed by specialized centers only. Randomized controlled trials are needed to further evaluate renal denervation. ",
keywords = "Antihypertensive Agents/therapeutic use, Clinical Trials as Topic, Combined Modality Therapy, Cooperative Behavior, Coronary Vasospasm/surgery, Germany, Humans, Hypertension/surgery, Interdisciplinary Communication, Renal Artery/innervation, Societies, Medical, Sympathectomy/methods",
author = "Oliver Vonend and Michael B{\"o}hm and Siegfried Eckert and Martin Hausberg and Harald Rittger and Lars-Christian Rump and Roland Schmieder and Karl-Ludwig Schulte and Heribert Schunkert and Michael Uder and Roland Veelken and Dierk Vorwerk and Joachim Weil and Ulrich Wenzel and Felix Mahfoud",
note = "{\textcopyright} Georg Thieme Verlag KG Stuttgart · New York.",
year = "2015",
month = mar,
doi = "10.1055/s-0041-100835",
language = "Deutsch",
volume = "140",
pages = "363",
journal = "DEUT MED WOCHENSCHR",
issn = "0012-0472",
publisher = "Georg Thieme Verlag KG",
number = "5",

}

RIS

TY - JOUR

T1 - Renale Denervation bei nicht-kontrollierter arterieller Hypertonie

AU - Vonend, Oliver

AU - Böhm, Michael

AU - Eckert, Siegfried

AU - Hausberg, Martin

AU - Rittger, Harald

AU - Rump, Lars-Christian

AU - Schmieder, Roland

AU - Schulte, Karl-Ludwig

AU - Schunkert, Heribert

AU - Uder, Michael

AU - Veelken, Roland

AU - Vorwerk, Dierk

AU - Weil, Joachim

AU - Wenzel, Ulrich

AU - Mahfoud, Felix

N1 - © Georg Thieme Verlag KG Stuttgart · New York.

PY - 2015/3

Y1 - 2015/3

N2 - Arterial hypertension is a major risk factor for cardiovascular mortality and remains insufficiently controlled in Germany. The sham controlled Symplicity HTN-3 trial did meet its primary safety endpoint but failed to meet its primary efficacy endpoint. Renal denervation can not replace established, well-proven therapies. It can only be used in selected truly resistant hypertensive patients as an additive approach and should be performed by specialized centers only. Randomized controlled trials are needed to further evaluate renal denervation.

AB - Arterial hypertension is a major risk factor for cardiovascular mortality and remains insufficiently controlled in Germany. The sham controlled Symplicity HTN-3 trial did meet its primary safety endpoint but failed to meet its primary efficacy endpoint. Renal denervation can not replace established, well-proven therapies. It can only be used in selected truly resistant hypertensive patients as an additive approach and should be performed by specialized centers only. Randomized controlled trials are needed to further evaluate renal denervation.

KW - Antihypertensive Agents/therapeutic use

KW - Clinical Trials as Topic

KW - Combined Modality Therapy

KW - Cooperative Behavior

KW - Coronary Vasospasm/surgery

KW - Germany

KW - Humans

KW - Hypertension/surgery

KW - Interdisciplinary Communication

KW - Renal Artery/innervation

KW - Societies, Medical

KW - Sympathectomy/methods

U2 - 10.1055/s-0041-100835

DO - 10.1055/s-0041-100835

M3 - SCORING: Zeitschriftenaufsatz

C2 - 25734680

VL - 140

SP - 363

JO - DEUT MED WOCHENSCHR

JF - DEUT MED WOCHENSCHR

SN - 0012-0472

IS - 5

ER -